Related Experiment Video
Updated: Jun 14, 2026

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program
Published on: April 19, 2019
Pharmacology Management in Improving Exercise Capacity of Patients with Fontan Circulation: A Systematic Review and
Brian Mendel1,2, Christianto1, Moira Setiawan1
1Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.
Insights
Bosentan treatment may improve exercise capacity in Fontan procedure patients by enhancing functional class and reducing heart rate. Further research is needed to fully understand its benefits for these patients.
Area of Science:
- Cardiology
- Pediatric Cardiology
- Clinical Pharmacology
Background:
- The Fontan procedure is a critical intervention for single ventricle physiology.
- Long-term complications of the Fontan procedure significantly impact patient quality of life.
- Improving exercise capacity is a key goal for managing Fontan patients.
Approach:
- A meta-analysis was conducted following PRISMA guidelines.
- Included studies were assessed for quality using the STROBE statement.
- Effectiveness of pharmacologic agents on exercise capacity in Fontan circulation was compared.
Key Points:
- Bosentan treatment significantly improved New York Heart Association Functional Class (NYHA FC) in Fontan patients.
- Neither bosentan nor sildenafil showed significant improvement in maximal oxygen consumption (VO2 max).
- Bosentan decreased post-exercise heart rate and improved 6-minute walking test results.
Conclusions:
- Bosentan may offer benefits for Fontan circulation patients, indirectly enhancing exercise capacity.
- Improvements include better NYHA FC and 6-minute walking test performance.
- More research is necessary to optimize exercise capacity in Fontan patients.
Background:
The Fontan procedure is currently the mainstay therapy for single functional ventricles. However, with prolonged follow-up duration, various complications have been observed that seriously influence the quality of life of patients.
Objectives:
The aim of this meta-analysis is to compare the effectiveness of pharmacologic agents in improving exercise capacity in patients with Fontan circulation.
Methods:
This meta-analysis was conducted according to the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) statement and has been registered in the International Prospective Register for Systematic Reviews database with registration no. 282352. Quality assessments of the included studies were assessed using the Strengthening Reporting of Observational Studies in Epidemiology (STROBE) statement.
Results:
Twelve studies met the predetermined inclusion criteria and were included in this metaanalysis. This meta-analysis found that treatment with bosentan significantly improved New York Heart Association Functional Class (NYHA FC) in Fontan patients (standard mean difference - 0.59, 95% CI -0.94 - -0.25; P=0.0008; I2 = 1%). However, the use of bosentan (P=0.66) and sildenafil (P=0.13) did not show a significant improvement in the maximum rate of oxygen consumption (VO2 max).
Conclusion:
This meta-analysis shows that people with Fontan circulation may benefit from using bosentan as it decreases postexercise heart rate and improves NYHA FC and 6-minute walking test results. Therefore, indirectly improving exercise capacity. Nonetheless, considerable work is required to strengthen our knowledge in improving the exercise capacity of Fontan patients.
More Related Videos
Related Concept Videos
Aortic Regurgitation IV: Nursing Management
Heart Failure V: Medical Management
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy VI: Nursing Management
Atherosclerosis III: Management
Peripheral Artery Disease III: Interprofessional Care

